BEIJING: A potential COVID-19 vaccine being developed by Chinese researchers showed promise in trials in monkeys, triggering antibodies and ...
BEIJING: A potential COVID-19 vaccine being developed by Chinese researchers showed promise in trials in monkeys, triggering antibodies and raising no safety issues, researchers said, and a human trial with more than 1,000 participants is under way.
The vaccine candidate, called BBIBP-CorV, induced high-level neutralising antibodies that can block the virus from infecting cells in monkeys, rats, guinea pigs and rabbits, researchers said in a paper published online by the medical journal Cell on Saturday ."These results support the further evaluation of BBIBP-CorV in a clinical trial," researchers said in the paper.
BBIBP-CorV, developed by Beijing Institute of Biological Products affiliated to state-owned China National Pharmaceutical Group , is among five candidates China is testing in humans. More than 100 potential COVID-19 vaccines are in various stages of development around the world. Among the front runners currently in human trials are those being developed by AstraZeneca, Pfizer, BioNtech, Johnson & Johnson, Merck, Moderna, Sanofi and China's CanSino Biologics.
As well as appearing safe and able to generate an immune response in animals, BBIBP-CorV did not appear to trigger antibodies that could boost the infection – a phenomenon known as antibody-dependent enhancement – the researchers said, although this does not necessarily guarantee ADE will not occur in human tests.Apart from BBIBP-CorV, Sinopharm, which has invested 1 billion yuan in vaccine projects, is testing in humans another vaccine candidate developed by its Wuhan-based unit.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Singapore to begin first human trial for potential Covid-19 treatmentSINGAPORE — Next week, 23 healthy volunteers here will be involved in a clinical safety trial for an antibody drug that is hoped to be a viable treatment for patients with Covid-19, a disease that has killed more than 400,000 around the globe so far.
Read more »
Singapore company to start clinical safety trials in humans for potential COVID-19 treatmentSINGAPORE: A Singapore-based company will start human clinical trials next week for a treatment that could slow down the progression of COVID-19 ...
Read more »
Mainland China reports 3 new confirmed, 5 asymptomatic COVID-19 casesMainland China reported three confirmed and five new asymptomatic COVID-19 cases by the end of Jun 9, the National Health Commission said on ...
Read more »
Hong Kong government to lead US$5 billion COVID-19 rescue package for Cathay PacificSYDNEY: Cathay Pacific Airways Ltd announced on Tuesday (Jun 9) a recapitalisation plan worth HK$39 billion (US$5.03 billion) led by the Hong Kong ...
Read more »
COVID-19 travel bans separate families even as lockdowns easeTOKYO: When Julie Sergent's father died, she faced an agonising decision: If she travelled from her home in Japan to attend the funeral in France, ...
Read more »